A. M. Nasonova

A. M. Nasonova

Auto-generated profile, based on publicly available information

A. M. Nasonova

State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Український радіологічний та онкологічний журнал
Verified
Journal Article
Open access
PDF file
OLO.P. Lukashova
O.P. Lukashova
HHH.I. Hradil
H.I. Hradil
ВСВ.п. Старенький
В.п. Старенький
ANA.M. Nasonova
A.M. Nasonova
АЗА.о. Закрутько
А.о. Закрутько
ГГГ.і. Граділь
Г.і. Граділь
Background. It is known that viral infections, such as pandemic influenza A(H1N1) and COVID-19, are characterized by acute respiratory distress syndrome, which in some cases is accompanied by high mortality. It has also been established that diffuse alveolar damage (DAD) is common to both influenza A and COVID-19. However, there are some differences between these infections. In contrast with pandemic flu, the most frequent symptom of COVID-19 is thromboembolic complications. The examination of the autopsy material showed that, despite the large number of conducted studies, the morphofunctional state of the hematoalveolar barrier of the lungs has not been sufficiently studied and some mechanisms of the development of pathological reactions of the оrganism in response to the action of influenza viruses A(H1N1) pdm09 and SARS-CoV-2 remain unclear. But the post-mortem picture of the hematoalveolar barrier can allow us to see all previous links of the viral lung damage process. This, in turn, will help to solve the problem of timely diagnosis of the disease severity, prognosis, prevention of further development of the disease and appropriate methods of therapy. The purpose of the work was to study the features of the SARS-CoV-2 virus effect on the morphofunctional state of the hematoalveolar region of the lungs at autopsy, which allows the pathogenesis of COVID-19 to clarified, critical mechanisms, thedevelopment of which leads to fatal consequences, to be established, and a therapy strategy to be proposed. Materials and methods. 8 samples of autopsy material of the lungs of patients with COVID-19 were studied. The comparison groups were patients with pandemic influenza A caused by the H1N1 virus (3 autopsies) and lung samples obtained during surgery from a patient with traumatic pneumothorax at a distance from the main focus. Lung samples were processed according to standard methods of biological material preparation for electron microscopy. From the obtained blocks, semi-thin sections with a thickness of 1 μm were made. They were stained with methylene blue, and studied under a light microscope at a magnification of 500 times. Digital photographs were obtained from the most informative areas. Ultrathin sections were analyzed in electron microscope after being contrasted in uranium and lead salts. The incidence of thrombosis in the studied groups was calculated. Statistical processing was performed using the Fisher’s non-parametric exact test and the Biostat PC software package. Results. The conducted studies showed that patients with pandemic influenza A had a pronounced lesion of the alveolar part of the lungs with damage to the alveolar walls of the lungs and the appearance of hyaline membranes in them. Desquamated pneumocytes, erythrocytes, neutrophilic leukocytes, macrophages and fibrin clots were found in alveoli filled with serous fluid. Among the features of the influenza virus, the preservation of cellular elements in the alveolar walls, the convergence of the alveolar septums and the formation of large areas with a high level of neutrophilic and macrophage invasion should be noted. Macrophages patrol the fields of damaged alveolar septums, separating them from the surrounding tissue. The subsequent fibrotization indicates the replacement of the destroyed lung tissue. The group of patients with COVID-19, in contrast to the pandemic flu, has significantly higher rates of thrombosis of various calibers. This is the result of disseminated intravascular coagulation, which often leads to fatal consequences. Erythrocytes in vascular thrombi have a tendency to agglutination, which is more pronounced in oncological patients. For all studied cases, epithelial membrane damage is characterized by almost complete loss of epithelial cells, which is accompanied by the denudation of capillaries, in which there is an accumulation of erythrocytes that gives them the look of «blood sausages». Sometimes these vessels are attached to hyaline membranes, sometimes they are arranged in chains or groups. No significant neutrophilic invasion or granulomatous inflammation is observed. Conclusions. The conducted studies showed that patients with pandemic influenza A had a pronounced lesion of the alveolar part of the lungs with a high level of neutrophilic and macrophage invasion. The mechanisms of the pathogenesis of COVID-19 are the direct destructive effect of the virus on the epithelial cells of the hemato-alveolar barrier, which obviously leads to the release of inflammatory cytokines that stimulate the systemic reaction of intravascular coagulation. It has been established that for oncology patients with a history of chemotherapy, the processes of thrombosis and destruction of alveolar walls during COVID-19 were one of the most pronounced lesions among the patients. The obtained results suggest that the fatal consequences of COVID-19 can obviously be prevented if therapeutic measures aimed at destroying the virus, blocking the targets for its penetration into cells, breaking the chain of intravascular blood coagulation with the use of corticosteroids, anticoagulants, cytokine inhibitors, etc. are taken immediately after receiving a positive diagnosis for COVID-19 and carrying out a set of laboratory tests to assess the severity of the disease.

17 December 2020 in Український радіологічний та онкологічний журнал
Verified
Journal Article
Open access
PDF file
HKH. V. Kulinich
H. V. Kulinich
RSR. M. Spuziak
R. M. Spuziak
ANA. M. Nasonova
A. M. Nasonova
LCL. V. Cherkasko
L. V. Cherkasko
MMM. V. Moskalenko
M. V. Moskalenko
ЕОЕ. Б. Орловська
Е. Б. Орловська
Background. The outbreak of the new coronavirus disease in 2019 (COVID19) has been the largest global health threat in the world, that infected more than 60 million people and killed more than 1,400,000. At the same time, cancer remains a widespread disease, from which more than 9.6 million patients in the world die each year. Accumulating data suggest that cancer patients are at higher risk of infection COVID-19 and severe course of the disease. This is due to immunosuppression, which is due to both the malignant tumor and antitumor therapy. Clinical manifestations of lung damage in cancer patients are not pathognomonic, because they can be caused by any pathological processes: metastatic lesions, inflammatory processes of viral and bacterial etiology, vascular disorders in the small circulation, etc. This requires not only to determine the nature of pathological changes in the lungs, but also to carry out their differential diagnosis in order to prescribe timely and adequate therapy. Purpose – elucidation of the relevance of X-ray diagnosis of pneumonia in cancer patients during the COVID-19 pandemic. Materials and methods. Follow-up of a patient K., 72 years old, who had coronavirus pneumonia along with complications (febrile neutropenia) resulting from chemoteraphy of recurrent endometrial leiomyosarcoma. The treatment was provided on the premises of Clinical Oncology and Hematology Department of State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine». Results and discussion. Over a period of 6 month, the patient was undergoing polychemotherapy (with complications like febrile neutropenia) of recurrent endometrial leiomyosarcoma. The control CT study detected pulmonary involvement. After receiving laboratory confirmation of COVID-19, was treated in the infectious department. The course of the disease was severe. Analyzing this clinical case of a patient with cancer in the process of special treatment, it is impossible to exclude the presence of progression in the lungs or drug pulmonitis. A favorable treatment result (negative PCR test, positive dynamics on CT) proves the non-metastatic nature of lung damage. Conclusions.. Diagnosis of COVID-19 infection should be based on the integrated application of clinical, radiological and laboratory research methods. Chest computed tomography, taking into account its high sensitivity, helps in diagnosis, control of the disease, playing an important role in the differential diagnosis and treatment tactics of COVID-19.

30 September 2025 in Український радіологічний та онкологічний журнал
Verified
Journal Article
Open access
PDF file
MHM.V. Havrylenko
M.V. Havrylenko
SAS.V. Artiukh
S.V. Artiukh
ANA.M. Nasonova
A.M. Nasonova
PSP.P. Sorochan
P.P. Sorochan
RSR.M. Spuziak
R.M. Spuziak
БМБ.і. Мельник
Б.і. Мельник
Background. The coronavirus infection poses additional challenges for the treatment of cancer patients due to the development of persistent multisystem disorders, which requires detailed investigation to optimize therapeutic approaches. Purpose – to determine the nature of radiological and functional changes in the cardiovascular and respiratory systems in cancer patients who have recovered from coronavirus infection and their relationship with clinical symptoms. Materials and Methods. A prospective cohort comparative study was conducted at the State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine» in Kharkiv (Ukraine) from 2022 to 2024. The study included 130 patients divided into the main group (67 patients with a history of coronavirus infection) and the control group (63 patients without it), who underwent a comprehensive clinical, laboratory, and instrumental assessment. Results. It was found that 49.2% of patients in the main group exhibited persistent manifestations of post-COVID syndrome within one year after the infection. The frequency of cancer therapy complications in this group was twice as high as in the control group (26.8% vs. 12.7). Radiological examination revealed predominantly interstitial changes in the lung parenchyma with ground-glass opacity (71.6%) and reticular pattern (41.8%), indicating postinfectious fibrosis formation. Functional testing showed a predominance of restrictive ventilatory disorders, the frequency of which increased after specific treatment from 22.4 to 35.8% (χ2=6.013; df=1; p=0.014). Laboratory parameters demonstrated persistent activation of hemostasis with elevated D-dimer levels (872±124 ng/mL; χ2=9.571; df=1; p<0.01) and an imbalance in cellular immunity with a reduced CD4+/CD8+ ratio (1.31±0.08). These findings indicate the systemic nature of post-COVID alterations, which decrease tolerance to the myeloand cardiotoxic effects of anticancer therapy. Conclusions. The results justify the need to develop personalized management protocols for cancer patients with post-COVID syndrome to enhance tolerance to anticancer treatment. The practical significance lies in identifying monitoring criteria for early detection and correction of systemic disorders to optimize therapeutic strategies and prevent complications in this category of patients

30 June 2026 in The Journal of V. N. Karazin Kharkiv National University, Series "Medicine"
Verified
Journal Article
Open access
PDF file
MKM.V. Krasnoselskyi
M.V. Krasnoselskyi
OSO.M. Sukhina
O.M. Sukhina
NPN.S. Pidchenko
N.S. Pidchenko
NMN.A. Mitriaieva
N.A. Mitriaieva
NAN.O. Artamonova
N.O. Artamonova
ANA.M. Nasonova
A.M. Nasonova
Background. Thyroid cancer is the most common malignant neoplasm of the endocrine system. Aggressive forms are characterized by an unfavorable prognosis and low effectiveness of standard treatment approaches. Therefore, the search for adjuvant agents with multitarget activity capable of modulating key signaling cascades of tumor progression is highly relevant. Particular interest is focused on metformin and resveratrol, which affect metabolic, inflammatory, and angiogenic mechanisms. Purpose – to systematize current data on the molecular mechanisms of action of metformin and resveratrol and to substantiate the feasibility of their use as adjuvant agents in the supportive therapy of aggressive forms of thyroid cancer, considering the role of the NF-κB–VEGF signaling axis. Materials and Methods. An analytical review of scientific publications indexed in Scopus, Web of Science Core Collection, and PubMed for the period 2015–2025 was conducted. Results. It was found that the NF-κB–VEGF axis forms a positive feedback loop via PI3K/ Akt/mTOR signaling, promoting tumor progression. Metformin activates AMPK, inhibits mTOR, suppresses NF-κB, and reduces VEGF expression. Resveratrol directly inhibits NF-κB, activates SIRT1, suppresses PI3K/Akt signaling, and decreases angiogenesis. The combined use of metformin and resveratrol provides a synergistic effect, manifested as multi-level suppression of signaling cascades, particularly the NF-κB–VEGF axis, and a potential disruption of the pathological feedback loop. Conclusions. Metformin and resveratrol are promising multitarget agents capable of modulating key mechanisms of tumor progression. Their combination may enhance therapeutic efficacy; however, this approach requires further confirmation in well-designed clinical studies.

2 July 2024 in Український радіологічний та онкологічний журнал
Verified
Journal Article
Open access
PSP.P. Sorochan
P.P. Sorochan
NPN.E. Prokhach
N.E. Prokhach
ANA.M. Nasonova
A.M. Nasonova
ІHІ.S. Hromakova
І.S. Hromakova
SAS.V. Artiukh
S.V. Artiukh
ІHІ.а. Hromakova
І.а. Hromakova
Background. In recent decades, immunotherapy has become a topical area of research in the complex treatment of oncological diseases. A significant achievement in the immunotherapy of oncological diseases was the discovery of immune checkpoint proteins, which are effective inhibitors of the immune response. Immune checkpoint inhibitors (ICIs) have been approved for the treatment of certain gastrointestinal malignancies. However, the clinical efficacy of ICIs monotherapy remains low. To improve the outcome of treatment, numerous studies are conducted in which immunotherapy is combined with other standard methods of anticancer treatment. Radiation therapy (RT) may enhance the antitumor immune response when combined with ICIs and is worth considering when combined with immunotherapy. The effectiveness of the combined strategy is actively being investigated in clinical trials. Purpose – to highlight the latest achievements in the field of combined use of immunotherapy with ICIs and RT in malignant neoplasms of the gastrointestinal tract. Materials and methods. Data searches for the review were conducted using PubMed, Scopus, Google Scholar, and ClinicalTrials.gov databases. The data of works published in 2013-2023 were analyzed and systematized. Results and discussion. The rationality of the combination of RT and immunotherapy was substantiated. The results of the combined use of neoadjuvant chemoradiotherapy (CRT) and immunotherapy with ICIs in patients with resectable esophageal cancer and combined treatment in patients with advanced disease are analyzed. The clinical results of the use of ICIs in combination with RT or CRT in patients with gastric cancer and the combination of ICIs and RT in patients with hepatocellular carcinoma are presented. The clinical effects of adding ICIs to neoadjuvant RT or CRT in patients with locally advanced and borderline resectable pancreatic cancer and the results of trials of a combined strategy in patients with advanced disease are characterized. The clinical efficacy of the combined approach in locally advanced rectal cancer, which is a routine area of RT application, and in metastatic disease is reviewed. The results of small studies of combined treatment involving patients with metastatic colorectal cancer are presented. Conclusions. Over the past decade, research in the field of immunotherapy for gastrointestinal tumors has increased significantly. Based on the synergistic effects of radiation therapy and immune checkpoint inhibitors, the combination of these therapeutic approaches is increasingly being tested in gastrointestinal cancer to improve treatment outcomes. Published studies have shown encouraging results with satisfactory toxicity. However, most clinical trials are retrospective, non-comparative phase I/II trials and are limited to a small number of patients. The results of these studies can serve as a basis for conducting multicenter prospective studies with large sample sizes to confirm the effectiveness of combined therapy.

30 June 2022 in Український радіологічний та онкологічний журнал
Verified
Journal Article
Open access
PDF file
HKH.V. Kulinich
H.V. Kulinich
EPE.B. Prokhorova
E.B. Prokhorova
MMM.V. Moskalenko
M.V. Moskalenko
ANA.M. Nasonova
A.M. Nasonova
SDS.V. Danyliuk
S.V. Danyliuk
ГКГ.в. Кулініч
Г.в. Кулініч
Background. Basal cell carcinoma (BCC) occupies around 80% of all the cases of diagnosed skin cancer (according to American Cancer Society). In various countries of the world the morbidity rate of BCC differs due to the main predisposing factor of BCC development – ultraviolet radiation. In Ukraine, according to National Cancer Registry, 15882 new cases of non-melanoma skin cancer were registered in 2019–2020. Standardized morbidity rate of this pathology increased by 2,6% compared to 2018. Basal cell cancer commonly recurs (according to different experts, the rate varies from 10% to 80%), at the same time, distant metastases are diagnosed quite rarely. Understanding contribution of Hedgehog (Hh) signaling pathway to carcinogenesis of BCC has become a serious achievement in molecular biology. In spite of relatively benign course of BCC and variety of treatment methods of this disease, there is a high risk of recurrence, and in some patients, lesions may progress to such extent that they become unsuitable for local therapy which makes it urgent to search for alternatives to surgery and radiation therapy. Purpose – to study the peculiarities of course, treatment, development of complications of recurrent, locally advanced, metastatic inoperable BCC by the example of clinical cases. Materials and methods. Clinical observation of female patient K., 73 years old, who was undergoing treatment in the Department of Clinical Oncology and Hematology by reason of multiple BCC lesions (observation time 14 years) and female patient D., 42 years old, who was undergoing treatment in the Department of Radiation Pathology and Palliative Care by reason of aggressive course of locally advanced form of basalioma (observation time 29 years). Observation and treatment were performed in the State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine». Results. The clinical cases of observation and different stages of treatment of patients with constantly recurring aggressive BCC over a long period of time, 14 and 29 years, are demonstrated. Metastasing of BCC is confirmed in both cases, local advancement is shown, various methods of treatment were used: surgery, radiation therapy, cryodestruction, chemotherapy. Difficulty of patients' management is shown, especially when all available methods are used up. Treatment of complications of special therapy methods, multistage restoring plastic surgeries using different methods of plastic repair are described. Conclusions. Treating recurrent, metastatic, and locally advanced inoperable forms of BCC when one runs out of possibilities of the main treatment methods – surgery, radiation therapy, chemotherapy is a difficult task which requires further development of modern technology and treatment methods.